Literature DB >> 33525371

PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery.

Giuseppe Ermondi1, Diego Garcia-Jimenez1, Giulia Caron1.   

Abstract

Targeted protein degradation by PROTACs has emerged as a new modality for the knockdown of a range of proteins, and, more recently, it has become increasingly clear that the PROTAC chemical space requires characterization through a pool of ad hoc physicochemical descriptors. In this study, a new database named PROTAC-DB that provides extensive information about PROTACs and building blocks was used to obtain the 2D chemical structures of about 1600 PROTACs, 60 E3 ligands, 800 linkers, and 202 warheads. For every structure, we calculated a pool of seven 2D descriptors carefully identified as informative for large and flexible structures. For comparison purposes, the same procedure was applied to a dataset of about 50 bRo5 approved drugs reported in the literature. Correlation matrices, PCAs, box plots, and other graphical tools were used to define and understand the chemical space covered by PROTACs and building blocks in relation to other compounds. Results show that linkers have different properties than E3 ligands and warheads. Polar descriptors additivity is not respected when passing from building blocks to degraders. Moreover, a very preliminary analysis based on three PROTACs with high, intermediate, and low permeability showed how the most permeable compounds seem to occupy a region closer to bRo5 drugs and, thus, exhibit different properties than impermeable compounds. Finally, a second database, PROTACpedia, was used to discuss the relevance of physicochemical descriptors on degradation activity.

Entities:  

Keywords:  2D physicochemical descriptors; PROTAC; chemical space; degrader; permeability

Mesh:

Substances:

Year:  2021        PMID: 33525371      PMCID: PMC7865272          DOI: 10.3390/molecules26030672

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  29 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  A MedChem toolbox for cereblon-directed PROTACs.

Authors:  Christian Steinebach; Izidor Sosič; Stefanie Lindner; Aleša Bricelj; Franziska Kohl; Yuen Lam Dora Ng; Marius Monschke; Karl G Wagner; Jan Krönke; Michael Gütschow
Journal:  Medchemcomm       Date:  2019-05-28       Impact factor: 3.597

Review 3.  Monitoring and deciphering protein degradation pathways inside cells.

Authors:  Danette L Daniels; Kristin M Riching; Marjeta Urh
Journal:  Drug Discov Today Technol       Date:  2018-12-19

Review 4.  Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.

Authors:  Scott D Edmondson; Bin Yang; Charlene Fallan
Journal:  Bioorg Med Chem Lett       Date:  2019-04-20       Impact factor: 2.823

Review 5.  Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.

Authors:  David A DeGoey; Hui-Ju Chen; Philip B Cox; Michael D Wendt
Journal:  J Med Chem       Date:  2017-09-27       Impact factor: 7.446

6.  Molecular properties that influence the oral bioavailability of drug candidates.

Authors:  Daniel F Veber; Stephen R Johnson; Hung-Yuan Cheng; Brian R Smith; Keith W Ward; Kenneth D Kopple
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

Review 7.  Drug Syntheses Beyond the Rule of 5.

Authors:  Mohit Tyagi; Fabio Begnini; Vasanthanathan Poongavanam; Bradley C Doak; Jan Kihlberg
Journal:  Chemistry       Date:  2019-10-11       Impact factor: 5.236

Review 8.  Targeted protein degradation: elements of PROTAC design.

Authors:  Stacey-Lynn Paiva; Craig M Crews
Journal:  Curr Opin Chem Biol       Date:  2019-04-17       Impact factor: 8.822

Review 9.  Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective.

Authors:  Andy Pike; Beth Williamson; Stephanie Harlfinger; Scott Martin; Dermot F McGinnity
Journal:  Drug Discov Today       Date:  2020-07-18       Impact factor: 7.851

Review 10.  CRISPR-Cas guides the future of genetic engineering.

Authors:  Gavin J Knott; Jennifer A Doudna
Journal:  Science       Date:  2018-08-31       Impact factor: 47.728

View more
  6 in total

1.  Cell Morphological Profiling Enables High-Throughput Screening for PROteolysis TArgeting Chimera (PROTAC) Phenotypic Signature.

Authors:  Maria-Anna Trapotsi; Elizabeth Mouchet; Guy Williams; Tiziana Monteverde; Karolina Juhani; Riku Turkki; Filip Miljković; Anton Martinsson; Lewis Mervin; Kenneth R Pryde; Erik Müllers; Ian Barrett; Ola Engkvist; Andreas Bender; Kevin Moreau
Journal:  ACS Chem Biol       Date:  2022-07-06       Impact factor: 4.634

2.  Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity.

Authors:  Victoria G Klein; Adam G Bond; Conner Craigon; R Scott Lokey; Alessio Ciulli
Journal:  J Med Chem       Date:  2021-12-09       Impact factor: 7.446

3.  Are we ready to design oral PROTACs®?

Authors:  Diego Garcia Jimenez; Matteo Rossi Sebastiano; Giulia Caron; Giuseppe Ermondi
Journal:  ADMET DMPK       Date:  2021-08-31

4.  PROTACs bearing piperazine-containing linkers: what effect on their protonation state?

Authors:  Jenny Desantis; Andrea Mammoli; Michela Eleuteri; Alice Coletti; Federico Croci; Antonio Macchiarulo; Laura Goracci
Journal:  RSC Adv       Date:  2022-08-09       Impact factor: 4.036

5.  Refinement of Computational Access to Molecular Physicochemical Properties: From Ro5 to bRo5.

Authors:  Matteo Rossi Sebastiano; Diego Garcia Jimenez; Maura Vallaro; Giulia Caron; Giuseppe Ermondi
Journal:  J Med Chem       Date:  2022-09-12       Impact factor: 8.039

6.  Designing Soluble PROTACs: Strategies and Preliminary Guidelines.

Authors:  Diego García Jiménez; Matteo Rossi Sebastiano; Maura Vallaro; Valentina Mileo; Daniela Pizzirani; Elisa Moretti; Giuseppe Ermondi; Giulia Caron
Journal:  J Med Chem       Date:  2022-04-25       Impact factor: 8.039

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.